Please login to the form below

Not currently logged in
Email:
Password:

NICE rejects Avastin for breast cancer

The National Institute for Health and Clinical Excellence has recommended against the use of Roche's Avastin for the treatment of metastatic breast cancer

In final draft guidance, the National Institute for Health and Clinical Excellence (NICE) has recommended against the use of Roche's Avastin (bevacizumab), in combination with a taxane, for the treatment of breast cancer which has spread to other parts of the body. 

In the guidance document (published December 8), NICE does not recommend the drug on the grounds that it offers limited and uncertain benefit for patients compared with existing treatments.

Sir Andrew Dillon, NICE CEO, said: "We know that it's immensely important for breast cancer patients, whose disease has spread, to prolong their lives as much as possible.

"Unfortunately, we did not receive any evidence from the manufacturer to show that bevacizumab can significantly lengthen a patient's life or, importantly, offer a better quality of life than existing treatments. Although the data seemed to show that the drug may slow the growth and spread of the cancer, the size of this effect varied between studies. Furthermore, it was extremely unclear that the benefits in terms of slowing tumour growth translated into benefits on overall survival, which is what really matters for patients."

NICE has made its decision regardless of the fact that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are currently reconsidering bevacizumab's licence as a treatment for metastatic breast cancer. Sir Andrew Dillon said, however, that should the FDA or EMA change their licensing decision, NICE would amend its advice to the NHS accordingly.

The draft guidance is subject to an appeal process whereby consultees can appeal for a reversal of the recommendation. Final guidance is expected to be published early in 2011. Before then, NHS bodies are able to make decisions locally on the funding of specific treatments.

9th December 2010

From: Healthcare

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Madmicrobe Studios

MadMicrobe is an award-winning team of certified medical illustrators creating animations that draw audiences into a world of suspense, excitement,...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....